Erythromycin ethylsuccinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for erythromycin ethylsuccinate and what is the scope of freedom to operate?
Erythromycin ethylsuccinate
is the generic ingredient in twelve branded drugs marketed by Azurity, Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Endo Operations, Ross Labs, Pharmacia And Upjohn, Arbor Pharms Llc, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Wyeth Ayerst, Aurobindo Pharma Usa, Barr, and Alra, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for erythromycin ethylsuccinate. Eight suppliers are listed for this compound.
Summary for erythromycin ethylsuccinate
US Patents: | 0 |
Tradenames: | 12 |
Applicants: | 17 |
NDAs: | 25 |
Drug Master File Entries: | 14 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 48 |
Clinical Trials: | 1 |
Patent Applications: | 8,715 |
What excipients (inactive ingredients) are in erythromycin ethylsuccinate? | erythromycin ethylsuccinate excipients list |
DailyMed Link: | erythromycin ethylsuccinate at DailyMed |
Recent Clinical Trials for erythromycin ethylsuccinate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Florida | Phase 2 |
Metabolic Solutions Inc. | Phase 2 |
Pharmacology for erythromycin ethylsuccinate
Drug Class | Macrolide Antimicrobial Macrolide |
Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for erythromycin ethylsuccinate
Anatomical Therapeutic Chemical (ATC) Classes for erythromycin ethylsuccinate
US Patents and Regulatory Information for erythromycin ethylsuccinate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-002 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Ross Labs | PEDIAZOLE | erythromycin ethylsuccinate; sulfisoxazole acetyl | GRANULE;ORAL | 050529-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-001 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Ani Pharms | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 062055-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.